TY  - JOUR
T1  - Symmetrical Drug-Related Rash and Acneiform Lesions in a Metastatic Colorectal Cancer Patient on Cetuximab
A1  - Rosa Coppola
A1  - Bianca Santo
A1  - Sonia Silipigni
A1  - Vincenzo Panasiti
JF  - Archive of International Journal of Cancer and Allied Science
JO  - Arch Int J Cancer Allied Sci
SN  - 3108-4834
Y1  - 2021
VL  - 1
IS  - 1
DO  - 10.51847/bkUwYBqODX
SP  - 1
EP  - 3
N2  - Advancements in targeted therapy have significantly influenced modern cancer treatment. Among these, epidermal growth factor receptor (EGFR) inhibitors are widely utilized for managing metastatic, recurrent, and advanced malignancies. This report discusses a 74-year-old male diagnosed with metastatic colorectal cancer who experienced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) alongside an acneiform eruption during cetuximab therapy in combination with FOLFOX chemotherapy. Examination revealed multiple superficial erosions accompanied by thin, light-brown to golden-yellow crusts and vegetating lesions. Concurrently, the patient exhibited a sharply demarcated symmetrical erythematous rash on the gluteal region. Given his medical history, a drug-induced reaction was suspected. Microbiological cultures from the crusted lesions around the mouth confirmed the presence of Staphylococcus aureus and Streptococcus anginosus, while cultures from the gluteal area were negative. The patient underwent treatment involving lesion cleansing, crust removal, wet dressings, and the application of fusidic acid cream to the affected mouth area, leading to complete resolution within two weeks. The erythema on the gluteal region was managed with topical steroids and zinc oxide cream, which resolved within one week. Additionally, prophylactic therapy with minocycline at a dosage of 100 mg per day was initiated for eight weeks.
UR  - https://smerpub.com/article/symmetrical-drug-related-rash-and-acneiform-lesions-in-a-metastatic-colorectal-cancer-patient-on-cet-pbypcro63opbf3g
ER  -